PhRMA Wants FDA To Explain When Decisions Depart From Committee Votes
Executive Summary
FDA should explain the why of its important regulatory decisions in consumer-friendly language, according to the Pharmaceutical Research and Manufacturers of America
You may also be interested in...
FDA Pushes Back Against “Living” Benefit-Risk Assessment Management Plan
The Institute of Medicine urges the agency to create a publicly available document setting forth benefits and risks of drugs, with periodic updates, but FDA says it has no extra resources to handle such an effort.
BIO Chairman Sees "Science-Driven" Hamburg As Plus For Regulatory Climate
BIO Board Chairman Stephen Sherwin is looking forward to an improved regulatory environment at FDA for biopharmaceutical companies with the advent of Margaret Hamburg as agency commissioner
BIO Chairman Sees "Science-Driven" Hamburg As Plus For Regulatory Climate
BIO Board Chairman Stephen Sherwin is looking forward to an improved regulatory environment at FDA for biopharmaceutical companies with the advent of Margaret Hamburg as agency commissioner